Gantenerumab, a candidate monoclonal antibody for the treatment of Alzheimer’s disease, has failed to slow progression of the disease in a large Phase 3 clinical programme involving 1,965 people across 30 countries, the developer Roche announced on 14 November. The company said it would share its learnings with the scientific community, while continuing to develop and test new diagnostics and prospective medicines for the disease.
